Huntsman declares $0.0875 quarterly dividend By Investing.com

Huntsman declared a quarterly dividend of $0.0875 per share, implying a 2.64% yield and extending its dividend streak to 20 consecutive years. However, recent operating results were weaker: Q4 adjusted loss was $0.37 per share versus a $0.33 loss expected, and revenue of $1.36 billion missed little but declined 7% year over year. Fitch downgraded Huntsman to BB+ with a negative outlook, while JPMorgan cut its rating to Neutral despite lifting its price target to $14.00.

Analysis

HUN is becoming a classic late-cycle value trap with a yield attached: the dividend helps define downside, but it does not solve the core issue that earnings quality is still weak and the market is already pricing in a recovery that may be too optimistic. The key second-order effect is balance-sheet optionality: when ratings move lower and outlooks stay negative, every incremental refinancing or working-capital swing matters more than headline EBITDA, because equity holders become residual claimants to cyclical timing rather than operational improvement.

The more interesting read-through is not to HUN alone but to the broader chemicals complex. If a relatively levered cyclical can trade near highs despite compressed profitability, then the market is effectively paying up for any name with even modest volume stability and pricing power; that favors better-capitalized peers and punishes small-cap commodity chem names with similar end-market exposure but weaker covenants. A sustained rally in HUN also implies investors are front-running a mid-2026 industrial recovery, which creates vulnerability if demand normalization slips even one or two quarters.

The dividend is likely to support the stock in the near term, but it also raises the odds of a “yield-then-cut” setup if margins stay depressed into the next two reporting cycles. From a trading lens, the asymmetry is now worse for longs than shorts: upside requires a clean cyclical rebound plus multiple expansion, while downside can re-rate quickly on any covenant, guidance, or ratings noise. The contrarian miss is that a steady dividend in a weak tape often looks defensive, but for cyclicals it can be a signal that management is preserving equity optics while the business still lacks earnings momentum.

Key Decisions for Investors

• Short HUN on strength or buy puts into the next earnings window; target 10-15% downside over 1-3 months if margins and guidance fail to inflect, with dividend support limiting the first leg lower.
• Pair long premium-quality chemical exposure vs short HUN over 3-6 months; the trade works if the market continues rewarding balance-sheet strength and punishing levered cyclicals with negative rating momentum.
• If holding HUN, use call overwriting or a collar rather than naked equity exposure; the implied upside is capped unless there is clear evidence of a 2026 earnings inflection, while downside from a guidance reset can be abrupt.
• Avoid chasing the stock ahead of the next quarter; wait for either a post-earnings flush or a confirmed upgrade in end-market data, because current pricing already discounts a meaningful cyclical recovery.